# An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct07589569/  
OnCo record `nct07589569` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HRS-7058 in pancreatic ductal adenocarcinoma, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer is a phase 2 interventional study registered as NCT07589569 by Shandong Suncadia Medicine Co., Ltd., with 92 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-7058.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07589569
- Phase: 2
- Setting: An Open, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07589569: https://clinicaltrials.gov/study/NCT07589569

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07589569.json